Bristol Vanlev Settlement Does Not Include Pre-Marketing Results Disclosure
Executive Summary
A settlement over allegations that Bristol-Myers Squibb misled investors about its investigational antihypertensive Vanlev does not establish disclosure guidelines for investigational products
You may also be interested in...
Merck Will Need VIGOR To Defend Vioxx Data Following NEJM Claims
The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication
Pargluva Panic: Need For Additional Trial Prompts Merck To Drop Partnership
Bristol-Myers Squibb remains in discussions with FDA about what clinical studies would be required to address concerns about the cardiovascular safety profile of its type 2 diabetes treatment candidate Pargluva (muraglitazar)
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer